Skip to content

Study on the difference evaluation of oral prednisone tablets in the treatment of different lymphocyte infiltration types of oral lichen planus

Study on the difference evaluation of oral prednisone tablets in the treatment of different lymphocyte infiltration types of oral lichen planus

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093223
Enrollment
Unknown
Registered
2024-11-29
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral lichen planus

Interventions

T lymphocyte infiltration group:Cluster of Differentiation 3
T-B lymphocyte infiltration group:Cluster of Differentiation 3,Cluster of Differentiation 20
T-P lymphocyte infiltration group:Cluster of Differentiation 3,Cluster of Differentiation 38
T-B-P lymphocyte infiltration group:Cluster of Differentiation 3, Cluster of Differentiation 20, Cluster of Differentiation 38

Sponsors

Ninth People 's Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age over 18 years old ; 2.Patients with oral lichen planus diagnosed according to medical history, clinical manifestations and pathological examination and VAS score = 1 ; 3.Voluntary participation in this study, can participate in the review on time and can complete the whole research steps ; 4.Patients agreed to participate in the study and voluntarily signed informed consent, and can voluntarily provide personal medical history ;

Exclusion criteria

Exclusion criteria: 1.Patients with drug allergy or allergic constitution in this study ; 2.Patients with other confirmed oral mucosal diseases, or oral lichen planus classified as white stripe type asymptomatic, or with severe dysplasia or canceration ; 3.Patients with more serious systemic diseases and tumors ; 4.Participated in other clinical researchers in the past 3 months ; 5.Some drugs or silver amalgam fillings may cause moss-like reactions ; 6. pregnant and lactating women and those preparing for pregnancy during the study period ( based on information provided by the subjects ) ; 7. due to other chronic diseases, including after transplantation, the need for regular use of antibiotics, hormones, non-steroidal anti-inflammatory drugs, immunosuppressants, immune enhancers, cytotoxic drugs, cell cycle drugs or anticoagulant drugs on the oral mucosa of drugs or preparations ; 8.Severe tobacco and alcohol addicts ( drinking > 15 units per week, each unit refers to : 350ml beer or 150ml wine or 50ml spirits ; smoking > 25 cigarettes / day ) ; 9. Any mental illness, or other illness that may lead to a legally recognized limitation of capacity to act.

Design outcomes

Primary

MeasureTime frame
Reticulation, Erythema, Ulceration (REU);

Countries

China

Contacts

Public ContactJunjun Chen

Ninth People 's Hospital, Shanghai Jiaotong University School of Medicine

2008chenjunjun@163.com+86 188 1782 1601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026